According to filings with the Securities and Exchange Commission, Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, Inc., executed a sale of company shares totaling $1,641,710 on May 13, 2026. The transaction involved the disposition of 20,000 common shares.
The sales were conducted at varying prices, ranging from $82.05 to $82.58 per share. Notably, these dispositions followed a pre-arranged trading plan established by Mr. Henderson on August 13, 2025, specifically under the framework of Rule 10b5-1.
The timing of this insider sale is set against several key corporate developments and market metrics for Apogee Therapeutics. Currently, the stock trades at $81.25. Over the past year, the shares have seen a substantial appreciation, rising nearly 100%. While the current price remains approximately 15% below its 52-week high of $95.31, some analysis from InvestingPro suggests that the company may be trading at elevated valuations.
Following this recent transaction, Mr. Henderson's direct holdings of Apogee Therapeutics common stock amount to 1,115,987 shares.
Recent Capitalization and Analyst Sentiment
In parallel developments bolstering market confidence, Apogee Therapeutics Inc. recently reported a successful capital raising effort. The company sold 5.75 million common shares at $70.00 per share, resulting in gross proceeds of approximately $403 million. This offering also included an additional tranche of 750,000 shares purchased by underwriters.
The positive momentum is further underscored by significant attention from major financial institutions and analyst firms. Several key reports reflect strong confidence in Apogee's therapeutic pipeline and overall financial strategy:
- Jefferies raised its price target to $120 while maintaining a Buy rating.
- Mizuho increased its price target to $110, citing recent data concerning zumilokibart for the treatment of atopic dermatitis.
- BTIG reiterated a Buy rating with an elevated price target of $137, specifically highlighting Apogee's 52-week APEX Part A results presented at a recent conference.
- Furthermore, Rothschild Redburn initiated coverage with a Buy rating and set a price target of $140. Their analysis focused heavily on Apogee’s lead asset, APG777, which is currently in development for atopic dermatitis.
These diverse developments illustrate sustained institutional interest in the company's therapeutic assets and financial execution.
Market Context and Investor Insight
The current trading data indicates that Apogee Therapeutics stock closed at $81.14, reflecting a daily change of 0.00% (as per one recorded session), though the article notes a prior reading of $81.25.
For investors seeking deeper analysis, resources are available providing comprehensive financial metrics and Fair Value assessments for APGE, alongside additional exclusive investment tips.